The latest price target for Cellectar Biosciences (NASDAQ:CLRB) was reported by Oppenheimer on October 11, 2024. The analyst firm set a price target for $14.00 expecting CLRB to rise to within 12 months (a possible 566.67% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Cellectar Biosciences (NASDAQ:CLRB) was provided by Oppenheimer, and Cellectar Biosciences reiterated their outperform rating.

There is no last upgrade for Cellectar Biosciences

There is no last downgrade for Cellectar Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectar Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectar Biosciences was filed on October 11, 2024 so you should expect the next rating to be made available sometime around October 11, 2025.

While ratings are subjective and will change, the latest Cellectar Biosciences (CLRB) rating was a reiterated with a price target of $14.00 to $14.00. The current price Cellectar Biosciences (CLRB) is trading at is $2.10, which is out of the analyst’s predicted range.